IP Library › Granted Patent US 12,415,784
Granted Patent B2
US 12,415,784 · App. 18/938,926 · Granted Sep 16, 2025

Cabozantinib compositions and methods of use

Inventors: Fang-Yu Liu (San Jose, CA); K.C. Sung (Tainan, TW); Yu Zhang (Hangzhou, CN); Shang Wei Qin (Hangzhou, CN); John Duan (Tainan, TW); George Kraft (San Jose, CA)
Assignee: Handa Oncology, LLC
C07D215/22A61K9/4816A61K9/4825A61K9/4858A61K9/4866A61K31/47C07C317/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,415,784
App. No.
18/938,926
Granted
Sep 16, 2025
Kind
B2
Abstract

The present invention relates to oral compositions comprising cabozantinib salts and at least one pharmaceutically acceptable excipient and methods of using the oral compositions to increase the oral bioavailability of the cabozantinib and reduce the adverse events associate with the oral administration of cabozantinib. The invention also relates to methods for preparing cabozantinib lauryl sulfate salts.

Claims (6)

1. A crystalline cabozantinib lauryl sulfate salt characterized by an x-ray powder diffraction (XRPD) pattern with 2θ peaks at 5.0±0.2, 12.1±0.2, 16.6±0.2, and 16.9±0.2.

2. The crystalline cabozantinib lauryl sulfate salt of claim 1 further comprising one or more XRPD 2θ peaks selected from the group consisting of 19.1±0.2, 24.5±0.2 and 29.5±0.2.

3. The crystalline cabozantinib lauryl sulfate salt of claim 1 comprising XRPD 2θ peaks at 5.0±0.2, 12.1±0.2, 16.6±0.2, 16.9±0.2, 19.1±0.2, 24.5±0.2 and 29.5±0.2.

4. A crystalline cabozantinib lauryl sulfate salt characterized by an x-ray powder diffraction (XRPD) pattern with 2θ peaks at 5.0±0.2, 12.1±0.2, 15.9±0.2, 16.6±0.2, and 16.9±0.2.

5. The crystalline cabozantinib lauryl sulfate salt of claim 4 further comprising one or more XRPD 2θ peaks selected from the group consisting of 19.2±0.2, 24.4±0.2 and 29.5±0.2.

6. The crystalline cabozantinib lauryl sulfate salt of claim 4 comprising XRPD 2θ peaks at 5.0±0.2, 12.1±0.2, 15.9±0.2, 16.6±0.2, 16.9±0.2, 19.2±0.2, 24.4±0.2 and 29.5±0.2.

Continuity (4)
Continuation PCTUS2024013450 · Jan 30, 2024
Provisional Application 63467388 · May 18, 2023
Provisional Application 63482334 · Jan 31, 2023
Related Publication 20250066305A1 · Feb 27, 2025
References Cited (169)
US 7579473B2 · Bannen et al. · 2009 [cited by applicant]
US 7798475B2 · Demirbüker · 2010 [cited by applicant]
US 7977345B2 · Bannen et al. · 2011 [cited by applicant]
US 8067436B2 · Bannen et al. · 2011 [cited by applicant]
US 8497284B2 · Bannen et al. · 2013 [cited by applicant]
US 8585942B2 · Demirbüker · 2013 [cited by applicant]
US 8585943B2 · Demirbüker · 2013 [cited by applicant]
US 8673912B2 · Cannon et al. · 2014 [cited by applicant]
US 8877776B2 · Brown et al. · 2014 [cited by applicant]
US 9174947B2 · Bannen et al. · 2015 [cited by applicant]
US 9365516B2 · Wilson et al. · 2016 [cited by applicant]
US 9456992B2 · Brisander et al. · 2016 [cited by applicant]
US 9717720B2 · Wilson et al. · 2017 [cited by applicant]
US 9724342B2 · Wilson et al. · 2017 [cited by applicant]
US 9809549B2 · Brown et al. · 2017 [cited by applicant]
US 9815789B2 · Jetti et al. · 2017 [cited by applicant]
US 9827230B2 · Brisander et al. · 2017 [cited by applicant]
US 9833442B2 · Brisander et al. · 2017 [cited by applicant]
US 9833443B2 · Brisander et al. · 2017 [cited by applicant]
US 9861624B2 · Aftab · 2018 [cited by applicant]
US 9969692B2 · Wilson et al. · 2018 [cited by applicant]
US 10034873B2 · Wilson et al. · 2018 [cited by applicant]
US 10039757B2 · Wilson et al. · 2018 [cited by applicant]
US 10053427B2 · Stefinovic et al. · 2018 [cited by applicant]
US 10080723B2 · Figueiredo et al. · 2018 [cited by applicant]
US 10123999B2 · Wilson · 2018 [cited by applicant]
US 10143683B2 · Brisander et al. · 2018 [cited by applicant]
US 10159666B2 · Aftab et al. · 2018 [cited by applicant]
US 10166225B2 · Aftab et al. · 2019 [cited by applicant]
US 10206916B2 · Stefinovic et al. · 2019 [cited by applicant]
US 10273211B2 · Aftab et al. · 2019 [cited by applicant]
US 10314830B2 · Brisander et al. · 2019 [cited by applicant]
US 10501418B2 · Aftab et al. · 2019 [cited by applicant]
US 10543206B2 · Wilson et al. · 2020 [cited by applicant]
US 10548888B2 · Wilson et al. · 2020 [cited by applicant]
US 10736886B2 · Aftab et al. · 2020 [cited by applicant]
US 10851061B2 · Aftab et al. · 2020 [cited by applicant]
US 10940149B1 · Liu et al. · 2021 [cited by applicant]
US 11007195B2 · Liu et al. · 2021 [cited by applicant]
US 11052088B2 · Liu et al. · 2021 [cited by applicant]
US 11065240B2 · Aftab et al. · 2021 [cited by applicant]
US 11091439B2 · Brown et al. · 2021 [cited by applicant]
US 11091440B2 · Brown et al. · 2021 [cited by applicant]
US 11098015B2 · Brown et al. · 2021 [cited by applicant]
US 11124481B2 · Xu et al. · 2021 [cited by applicant]
US 11124482B2 · Bannen et al. · 2021 [cited by applicant]
US 11141413B2 · Aftab et al. · 2021 [cited by applicant]
US 11160805B2 · Liu et al. · 2021 [cited by applicant]
US 11261160B2 · Srinivasan et al. · 2022 [cited by applicant]
US 11279675B2 · Shah · 2022 [cited by applicant]
US 11433064B2 · Aftab et al. · 2022 [cited by applicant]
US 11498902B2 · Amala et al. · 2022 [cited by applicant]
US 11590122B2 · Dube et al. · 2023 [cited by applicant]
US 11679105B1 · Dube et al. · 2023 [cited by applicant]
US 11724986B2 · Aftab et al. · 2023 [cited by applicant]
US 11731941B2 · Shah · 2023 [cited by applicant]
US 12064430B2 · Liu et al. · 2024 [cited by applicant]
US 20070054928A1 · Bannen et al. · 2007 [cited by applicant]
US 20090274693A1 · Gilmer et al. · 2009 [cited by applicant]
US 20100143459A1 · Leipold et al. · 2010 [cited by applicant]
US 20120070368A1 · Bannen et al. · 2012 [cited by applicant]
US 20120252840A1 · Aftab et al. · 2012 [cited by applicant]
US 20120270872A1 · Cannon et al. · 2012 [cited by applicant]
US 20120282179A1 · Aftab et al. · 2012 [cited by applicant]
US 20130030172A1 · Wilson et al. · 2013 [cited by applicant]
US 20130093111A1 · Demirbüker et al. · 2013 [cited by applicant]
US 20130143881A1 · Cannon et al. · 2013 [cited by applicant]
US 20130197230A1 · Wilson et al. · 2013 [cited by applicant]
US 20130330377A1 · Wilson · 2013 [cited by applicant]
US 20130337015A1 · Wilson · 2013 [cited by applicant]
US 20140044819A1 · Demirbüker · 2014 [cited by applicant]
US 20140057908A1 · Smith et al. · 2014 [cited by applicant]
US 20140057943A1 · Smith et al. · 2014 [cited by applicant]
US 20140066444A1 · Smith et al. · 2014 [cited by applicant]
US 20140121239A1 · Aftab · 2014 [cited by applicant]
US 20140179736A1 · Schwab et al. · 2014 [cited by applicant]
US 20140200242A1 · Wilson · 2014 [cited by applicant]
US 20140221372A1 · Kulkarni et al. · 2014 [cited by applicant]
US 20140228401A1 · Aftab et al. · 2014 [cited by applicant]
US 20140235631A1 · Bunt et al. · 2014 [cited by applicant]
US 20140256938A1 · Wilson et al. · 2014 [cited by applicant]
US 20140323522A1 · Aftab et al. · 2014 [cited by applicant]
US 20140330170A1 · Holland · 2014 [cited by applicant]
US 20140378454A1 · Brisander et al. · 2014 [cited by applicant]
US 20150133494A1 · Aftab · 2015 [cited by applicant]
US 20160022662A1 · DeCillis · 2016 [cited by applicant]
US 20160031818A1 · Aftab · 2016 [cited by applicant]
US 20160082019A1 · Sweeney et al. · 2016 [cited by applicant]
US 20160250153A1 · Brisander et al. · 2016 [cited by applicant]
US 20160361313A1 · Brisander et al. · 2016 [cited by applicant]
US 20170042828A1 · Figueiredo et al. · 2017 [cited by applicant]
US 20170044106A1 · Aftab et al. · 2017 [cited by applicant]
US 20170087143A1 · Aftab et al. · 2017 [cited by applicant]
US 20170143689A1 · Wilson et al. · 2017 [cited by applicant]
US 20170209372A1 · Temtem et al. · 2017 [cited by applicant]
US 20170217896A1 · Xu et al. · 2017 [cited by applicant]
US 20170224672A1 · Aftab et al. · 2017 [cited by applicant]
US 20170266178A1 · Wilson et al. · 2017 [cited by applicant]
US 20170281559A1 · Chaudhary · 2017 [cited by applicant]
US 20180042906A1 · Brisander et al. · 2018 [cited by applicant]
US 20180326078A1 · Yang et al. · 2018 [cited by applicant]
US 20190133935A1 · Sommer et al. · 2019 [cited by applicant]
US 20190167630A1 · Bunt et al. · 2019 [cited by applicant]
US 20190209547A1 · Aftab et al. · 2019 [cited by applicant]
US 20190262330A1 · Schwab et al. · 2019 [cited by applicant]
US 20190352403A1 · Schwab et al. · 2019 [cited by applicant]
US 20200113903A1 · Liu et al. · 2020 [cited by applicant]
US 20200188400A1 · Liu et al. · 2020 [cited by applicant]
US 20200255382A1 · Schwab et al. · 2020 [cited by applicant]
US 20200268737A1 · Shah et al. · 2020 [cited by applicant]
US 20200330451A1 · Aftab et al. · 2020 [cited by applicant]
US 20210030737A1 · Tolaney et al. · 2021 [cited by applicant]
US 20210046077A1 · Liu et al. · 2021 [cited by applicant]
US 20210161885A1 · Wilson et al. · 2021 [cited by applicant]
US 20210161895A1 · Liu et al. · 2021 [cited by applicant]
US 20210188776A1 · Amala et al. · 2021 [cited by applicant]
US 20210261509A1 · Shah · 2021 [cited by applicant]
US 20210275515A1 · Apolo · 2021 [cited by applicant]
US 20210283133A1 · Liu et al. · 2021 [cited by applicant]
US 20210315815A1 · Ni et al. · 2021 [cited by applicant]
US 20210332014A1 · Chen et al. · 2021 [cited by applicant]
US 20220265633A1 · Dube et al. · 2022 [cited by applicant]
US 20220280500A1 · Dube et al. · 2022 [cited by applicant]
US 20220362235A1 · Dube et al. · 2022 [cited by applicant]
US 20220387418A1 · Dube et al. · 2022 [cited by applicant]
US 20230142737A1 · Liu et al. · 2023 [cited by applicant]
US 20230149384A1 · Schwab et al. · 2023 [cited by applicant]
US 20230181559A1 · Aftab et al. · 2023 [cited by applicant]
US 20240366603A1 · Liu et al. · 2024 [cited by applicant]
CA 3135464 · 2023 [cited by applicant]
CN 103664776 · 2014 [cited by applicant]
CN 107556238 · 2018 [cited by applicant]
WO 2008055966 · 2008 [cited by applicant]
WO 2013055996 · 2013 [cited by applicant]
WO 2016020697 · 2016 [cited by applicant]
WO WO2019241504A1 · 2019 [cited by examiner]
WO 2022115464 · 2022 [cited by applicant]
WO 2022177983 · 2022 [cited by applicant]
WO 2023088284 · 2023 [cited by applicant]
WO 2023165948 · 2023 [cited by applicant]
WO 2023179774 · 2023 [cited by applicant]
WO 2024114710 · 2024 [cited by applicant]
WO 2024163400 · 2024 [cited by applicant]
International Search Report for PCT/US2024/013450 dated May 31, 2024. [cited by applicant]
Written Opinion for PCT/US2024/013450 dated May 31, 2024. [cited by applicant]
Morcos et al., “Effects of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results from a Bioequivalence Study in Healthy Subjects” Clinical Pharmacology in Drug Development, vol. 6, No. 3,… [cited by applicant]
Mallikarjun et al., “In-Vitro and Kinetic Studies of Immediate Release Sorafenib Tosylate Film Coated Tablets,” World Journal of Pharmaceutical Research, vol. 7, May 1, 2018, pp. 931-944. [cited by applicant]
CABOMETYX Package Insert Dec. 2017. [cited by applicant]
COMETRIQ Package Insert Oct. 2017. [cited by applicant]
Liu et al., “Improving Oral Bioavailability of Sorafenib by Optimizing the “Spring” and “Parachute” Based on Molecular Interaction Mechanism,” Mol. Pharm.Feb. 2016. 1:13(2): 599-608. [cited by applicant]
Sharma et al., “The Concomitant Use of Tyrosinr Kinase Inhibitors and Proton Pump Inhibitors: Prevalence, Predictors, and Impact on Survival and Discontinuation of Therapy in Older Adults with cancer,” Jan. 2019. [cited by applicant]
BASF Brochure Solubility Enhancement with BASF Pharma Polymers, Oct. 2011. [cited by applicant]
CAPMUL Technical Data Sheet Feb. 14, 2014. [cited by applicant]
BASF Brochure Pharma Solution Product Overview 2018 Dec. 2017. [cited by applicant]
CAPMUL Brochure Dec. 2015. [cited by applicant]
Sharma, M., et al. “The Prevalence and Predictors of Concomitant use of Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Older Adults with Cancer: An Observational Study Using Seer-Medicare Data.” Value in Healt… [cited by applicant]
ABITEC Personal Care Products Brochure, downloaded Jun. 25, 2020. [cited by applicant]
ABITEC Food, Flavor & Nutrition Brochure, downloaded Jun. 25, 2020. [cited by applicant]
K.C. Panigrahi, et al., “Gelucire: A Versatile Polymer for Modified Release Drug Delivery System,” Future Journal of Pharmaceutical Sciences (Nov. 2017), https://doi.org/10.1016/j.fjps.2017.11.001. [cited by applicant]
Daublain P, Feng K-I, Altman MD, Martin I, Mukherjee S, Nofsinger R, et al. Analyzing the Potential Root Causes of Variability of Pharmacokinetics in Preclinical Species. Mol Pharm. Mar. 2017; 14:1634-45. doi: 10.1021/a… [cited by applicant]
Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet. Mar. 1999;36:233-54. [cited by applicant]
Charman WN, Porter C, Methani S, Dressman JB. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of pH and lipids. J Pharm Sci. Mar. 1997;86:269-82. [cited by applicant]
Chen, Mei-Ling (2008): Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. In Advanced drug delivery reviews, Nov. 2017, 60 (6), pp. 768-777. DOI: 10.1016/j.addr.2007.09.010. [cited by applicant]
Porter, Christopher J. H.; Trevaskis, Natalie L.; Charman, William N. (2007): Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. In Nature reviews. Drug discovery, Mar. 2007, 6 (3), p… [cited by applicant]
Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070241.pdf, Dec. 2002. [cited by applicant]
Kasashima et al. “Oral Sustained-Release Suspension Based on a Lauryl Sulfate Salt/Complex,” International Journal of Pharmaceutics, 2016, pp. 677-683 (available online Oct. 17, 2016). [cited by applicant]
Kasashima et al., “Oral Sustained Release of a Hydrophilic Drug Using the Lauryl Sulfate Salt/Complex,” Chem. Pharm. Bull. May 2016; 64(9); pp. 1304-1309 (Abstract). [cited by applicant]
Kasashima et al., “Oral Sustained Release of a Hydrophilic Drug Using the Lauryl Sulfate Salt/Complex,” Chem. Pharm. Bull. May 2016; 64(9); pp. 1304-1309. [cited by applicant]
O'Brien “Small Molecule Kinase Inhibitors Approved by the FDA From 2000 to 2011: A Systematic Review of Preclinical ADME Data,” Expert Opinion on Drug Metabolism & Toxicology, 9:12, 1597-1612, Aug. 31, 2013. [cited by applicant]